Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Darren Abbanat"'
Autor:
Carlos A. Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Tracey A. Day, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract The safety, reactogenicity, and immunogenicity of 3 doses of ExPEC10V (VAC52416), a vaccine candidate to prevent invasive Escherichia coli disease, were assessed in a phase 1/2a study (NCT03819049). In Cohort 1, ExPEC10V was well tolerated;
Externí odkaz:
https://doaj.org/article/cf2074de9415429ca03e908b467aa4d5
Autor:
Megumi Inoue, Tetsuro Ogawa, Hiroshi Tamura, Yosuke Hagiwara, Yuki Saito, Darren Abbanat, Germie van den Dobbelsteen, Peter Hermans, Stefan Thoelen, Jan Poolman, Patricia Ibarra de Palacios
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 9, Pp 2150-2157 (2018)
This Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and immunogenicity of different doses of ExPEC4V conjugate vaccine (4-16µg Polysaccharide [PS]/serotype) in healthy Japanese particip
Externí odkaz:
https://doaj.org/article/3d23f7a5c4eb41e297ef09fea55d7ac9
Autor:
Steven A. Rosenberg, Neal D. Shore, Yosuke Hagiwara, Bart Spiessens, Marc J. M. Bonten, Patricia Ibarra de Palacios, Wouter Haazen, Jan Poolman, Florian M.E. Wagenlehner, Peter W. M. Hermans, Jeroen Geurtsen, Oscar Go, Darren Abbanat
Publikováno v:
Journal of Urology. 205:826-832
Purpose:Extraintestinal pathogenic Escherichia coli (ExPEC) are a leading cause of invasive infections in adults. The study aimed to evaluate the incidence of microbiologically confirmed invasive E...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f330a2b9eff518d3daa71508949eb2ce
https://doi.org/10.1097/ju.0000000000001425
https://doi.org/10.1097/ju.0000000000001425
Autor:
Steven Rosenberg, Marc Bonten, Wouter Haazen, Bart Spiessens, Darren Abbanat, Oscar Go, Florian Wagenlehner, Neal Shore, Yosuke Hagiwara, Patricia Ibarra de Palacios, Jeroen Geurtsen, Peter Hermans, Jan Poolman
Publikováno v:
The Journal of urology. 205(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a359dd5068413a84a89bf63077280f23
https://pubmed.ncbi.nlm.nih.gov/33403864
https://pubmed.ncbi.nlm.nih.gov/33403864
Autor:
Bart Spiessens, Curtis J. Donskey, Patricia Ibarra de Palacios, Stefan Gravenstein, Elie Saade, Brigid Wilson, Peter Hermans, Jan Poolman, Darren Abbanat
Publikováno v:
Vaccine. 38(33)
There is an increasing incidence of infectious complications caused by extraintestinal pathogenic Escherichia coli (ExPEC) after transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB), and a need for prophylaxis methods effective against ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c2f11959f30bcc591687dda0cc1817
https://pubmed.ncbi.nlm.nih.gov/32561123
https://pubmed.ncbi.nlm.nih.gov/32561123
Autor:
Darren Abbanat, Yuki Saito, Patricia Ibarra de Palacios, Stefan Thoelen, Tetsuro Ogawa, Germie van den Dobbelsteen, Hiroshi Tamura, Yosuke Hagiwara, Peter Hermans, Jan Poolman, Megumi Inoue
Publikováno v:
Human Vaccines & Immunotherapeutics
This Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and immunogenicity of different doses of ExPEC4V conjugate vaccine (4-16µg Polysaccharide [PS]/serotype) in healthy Japanese particip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ffa2b9c8f02b6c942db368a540949b
http://europepmc.org/articles/PMC6183137
http://europepmc.org/articles/PMC6183137
Autor:
Darren Abbanat, Enos Bernasconi, Stéphan Juergen Harbarth, Ingrid van den Nieuwenhof, Anette Kuhn, P. Martín, Serge de Vallière, Stefan Thoelen, Rahel Frölich, Germie van den Dobbelsteen, Todd A. Davies, Christoph Hatz, Tanja Hülder, Angela Huttner, Anita M. Dreyer, Volker Viereck, Veronica Gambillara Fonck, Gloria Ryu, Kerstin Kling, Sabine Gröger, Jan Poolman, Cristina Alaimo, Alena Hornacek, David Scheiner, Kellen Fae, Tilemachos Kavvadias
Publikováno v:
The Lancet Infectious Diseases, Vol. 17, No 5 (2017) pp. 528-537
BACKGROUND Escherichia coli infections are increasing worldwide in community and hospital settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety and immunogenicity of a bioconjugate vaccine containing the O-antige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53b08576980adde2c05ab333e1587296
https://doi.org/10.1016/s1473-3099(17)30108-1
https://doi.org/10.1016/s1473-3099(17)30108-1
Autor:
Bart Spiessens, Darren Abbanat, Stefan Thoelen, Jan Poolman, Patricia Ibarra de Palacios, John E Ervin, Robert W. Frenck, Oscar Go, Wouter Haazen, Laurence Chu, Germie van den Dobbelsteen
Publikováno v:
The Lancet. Infectious diseases. 19(6)
Summary Background ExPEC4V (JNJ-63871860) is a bioconjugate vaccine, containing O-antigens from Escherichia coli serotypes O1A, O2, O6A, and O25B, developed for the prevention of invasive extra-intestinal pathogenic E coli (ExPEC) disease. We aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25748b9aaa3652eb5c6ee4ccee085083
https://pubmed.ncbi.nlm.nih.gov/31079948
https://pubmed.ncbi.nlm.nih.gov/31079948
Autor:
Darren Abbanat, Wenchi Shang, Karen Amsler, Colleen Santoro, A. Simon Lynch, Ellen Z. Baum, Steven Crespo-Carbone
Publikováno v:
International Journal of Antimicrobial Agents. 43:32-39
The aim of this study was to evaluate the in vitro efficacy of ceftobiprole and comparator antibiotics, either alone or in combination, in staphylococcal MBEC™ (minimum biofilm eradication concentration) and colony biofilm assays at dilutions of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a712d620676edf1d16f08d3673e0e6
https://doi.org/10.1016/j.ijantimicag.2013.09.013
https://doi.org/10.1016/j.ijantimicag.2013.09.013
Autor:
Stefan Thoelen, Bart Spiessens, Tiziano de Rosa, Jan Poolman, Oscar Go, Darren Abbanat, Wouter Haazen, Patricia Ibarra de Palacios, William B Smith, Kellen Fae
Publikováno v:
Open Forum Infectious Diseases
Background The ExPEC4V vaccine contains 4 Escherichia coli O-antigens (O1A, O2, O6A, O25B) conjugated to exotoxin protein A and is being studied for prevention of Invasive Extraintestinal pathogenic E. coli (ExPEC) Disease (IED). This phase-2 double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce40e068736c2aa092c8489aea260a00
http://europepmc.org/articles/PMC6810236
http://europepmc.org/articles/PMC6810236